Ethiopia has successfully declared the end of its first-ever Marburg Virus Disease (MVD) outbreak. This announcement follows a period of enhanced surveillance where no new confirmed cases were identified. Consequently, the World Health Organization (WHO) confirmed the end of the outbreak on Monday. The highly infectious disease, which is clinically similar to Ebola, tragically killed at least nine people in the Horn of Africa country after its announcement on November 14.
Understanding Marburg Virus Disease (MVD)
Marburg Virus Disease is a severe and often fatal illness in humans. It belongs to the Filoviridae family, the same one as the Ebola virus. The MVD virus is initially transmitted to people from Rousettus aegyptiacus fruit bats. Subsequently, human-to-human transmission occurs through direct contact with an infected person’s bodily fluids (including blood, faeces, and vomitus) or contaminated surfaces and materials. Furthermore, transmission can happen through infected semen for up to seven weeks after clinical recovery. Therefore, healthcare workers and caregivers face a particularly high risk when appropriate infection prevention and control (IPC) measures are not strictly followed. The disease has an incubation period of two to 21 days.
Clinical Presentation and Management
The onset of MVD is typically abrupt. Patients initially experience a high fever, severe headache, and profound malaise. Moreover, muscle aches are a common early feature. Severe gastrointestinal symptoms, such as watery diarrhoea, nausea, and vomiting, may start around the third day. Haemorrhagic manifestations—including bleeding from the nose, gums, and internal sites—can develop from day five. These symptoms escalate quickly, often leading to shock, liver failure, and multi-organ dysfunction. Previous MVD outbreaks have resulted in case fatality rates ranging dramatically from 24% to 88%. In fact, the fatality often occurs within eight to nine days of symptom onset. Critically, there are currently no approved vaccines or specific antiviral treatments for MVD. Consequently, early supportive care, including rehydration and symptomatic treatment, is paramount and significantly improves patient survival. Doctors should consider MVD as a differential diagnosis in travelers returning from endemic regions with compatible symptoms, aligning with national preparedness guidelines. For those interested in reinforcing core emergency management skills, understanding the appropriate response to severe infectious disease outbreaks is essential, as seen in the Certification Course In Emergency Medicine.
Frequently Asked Questions
Q1: What is the Marburg Virus Disease fatality rate?
The average case fatality rate (CFR) for Marburg Virus Disease is approximately 50%. However, CFRs in past outbreaks have varied widely, ranging from 24% to as high as 88% of cases, highlighting the severity of the illness.
Q2: How is Marburg Virus Disease transmitted?
Marburg Virus Disease is primarily transmitted to humans from infected Rousettus aegyptiacus fruit bats. Human-to-human transmission then occurs through direct contact with an infected person’s blood, body fluids, or through indirect contact with contaminated surfaces and materials. Recognizing and implementing strict infection prevention and control (IPC) measures is vital in managing high-consequence pathogens.
Q3: Is there a specific treatment for Marburg Virus Disease?
There are currently no approved vaccines or specific antiviral treatments available for MVD. Management focuses on early, aggressive supportive care, including maintaining the patient’s fluid and electrolyte balance and treating symptoms.
References
- Ethiopia declares end of Marburg outbreak that killed nine – ETHealthworld
- World Health Organization (WHO). Marburg Virus Disease Fact Sheet.
- Africa CDC. Marburg Virus Disease (MVD): Transmission, Symptoms, Prevention, Treatment.
- National Centre for Disease Control (NCDC), India. CD Alert – Marburg Virus Disease.
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.